Preoperative CA-125 levels in patients with hereditary compared to sporadic epithelial ovarian carcinoma.
Preoperative CA-125 levels in patients with hereditary compared to sporadic epithelial ovarian carcinoma.
复制标题
遗传性上皮性卵巢癌患者与散发性上皮性卵巢癌患者术前 CA-125 水平的比较。
DOI：
10.1006/gyno.2001.6538
复制
发表时间：
2002
期刊：
影响因子：
--
通讯作者：
Boyd,Jeff
中科院分区：
文献类型：
--
作者：
Leitao,Mario;Boyd,Jeff
本研究的目的是确定BRCA相关的遗传性卵巢癌患者和散发性卵巢癌患者之间术前CA-125水平是否存在显著差异，以及CA-125水平是否可预测最佳细胞减灭术的可能性。术前CA-125水平的数据可用于49/88（56%）遗传性病例和43/101（43%）散发性病例。获得了所有92例具有可用CA-125数据的患者的手术细胞减灭程度数据。采用Kruskal-Wallis χ 2检验比较遗传组和散发组术前CA-125水平。手术cytoreduction与术前CA-125水平的相关性进行了评估，使用Fisher精确test.ResultsMean术前CA-125水平之间没有显着差异BRCA 1（2289 U/ml），BRCA 2（2586 U/ml），和散发（3307 U/ml）的情况下（P = 0.5）。对于遗传性病例，59%术前CA-125水平<500 U/ml的患者和52%术前水平>500 U/ml的患者实现了最佳细胞减灭。对于散发性病例，62%的CA-125水平<500 U/ml的患者和20%的CA-125水平>500 U/ml的患者实现了最佳细胞减少（P = 0.01）。对于遗传性病例，最佳细胞减灭术的可能性与术前CA-125水平无关，但对于CA-125水平>500 U/ml的散发性病例，最佳细胞减灭术的可能性显著降低。
ObjectiveThe aim of this study was to determine whether a significant difference in preoperative CA-125 levels exists between patients with BRCA-associated hereditary ovarian carcinoma and those with sporadic ovarian carcinoma and whether the CA-125 level predicts the probability of optimal cytoreductive surgery.MethodsFrom a retrospective cohort of 189 consecutive ovarian cancer patients genotyped for BRCA mutation status, data on preoperative CA-125 levels were available for 49/88 (56%) hereditary cases and 43/101 (43%) sporadic cases. Data on the extent of surgical cytoreduction were obtained for all 92 patients with available CA-125 data. Comparison of preoperative CA-125 levels between hereditary and sporadic groups was assessed using the Kruskal–Wallis χ2test. Correlation of surgical cytoreduction with preoperative CA-125 level was assessed using Fisher's exact test.ResultsMean preoperative CA-125 levels were not significantly different among BRCA1 (2289 U/ml), BRCA2 (2586 U/ml), and sporadic (3307 U/ml) cases (P = 0.5). For hereditary cases, optimal cytoreduction was achieved in 59% of patients with preoperative CA-125 levels of <500 U/ml and in 52% of patients with preoperative levels >500 U/ml. For sporadic cases, optimal cytoreduction was achieved in 62% of patients with CA-125 levels of <500 U/ml and in 20% of patients with levels >500 U/ml (P = 0.01).ConclusionsPreoperative CA-125 levels are not significantly different for patients with hereditary compared to sporadic ovarian carcinoma. The probability of optimal cytoreduction is independent of the preoperative CA-125 level for hereditary cases, but optimal cytoreduction is significantly less likely for sporadic cases with CA-125 levels of >500 U/ml.